244 related articles for article (PubMed ID: 32239624)
21. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
[TBL] [Abstract][Full Text] [Related]
22. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
23. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
Li L; Wang Y; Jiao L; Lin C; Lu C; Zhang K; Hu C; Ye J; Zhang D; Wu H; Feng M; He Y
Cancer Lett; 2019 Jun; 452():191-202. PubMed ID: 30910592
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
Chen W; Yu D; Sun SY; Li F
Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
[TBL] [Abstract][Full Text] [Related]
25. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
[TBL] [Abstract][Full Text] [Related]
26. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
27. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Sun Y; Meyers BA; Czako B; Leonard P; Mseeh F; Harris AL; Wu Q; Johnson S; Parker CA; Cross JB; Di Francesco ME; Bivona BJ; Bristow CA; Burke JP; Carrillo CC; Carroll CL; Chang Q; Feng N; Gao G; Gera S; Giuliani V; Huang JK; Jiang Y; Kang Z; Kovacs JJ; Liu CY; Lopez AM; Ma X; Mandal PK; McAfoos T; Miller MA; Mullinax RA; Peoples M; Ramamoorthy V; Seth S; Spencer ND; Suzuki E; Williams CC; Yu SS; Zuniga AM; Draetta GF; Marszalek JR; Heffernan TP; Kohl NE; Jones P
Cancer Res; 2020 Nov; 80(21):4840-4853. PubMed ID: 32928921
[TBL] [Abstract][Full Text] [Related]
28. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
29. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
[TBL] [Abstract][Full Text] [Related]
30. Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.
Cao L; Qin Z; Yu T; Bai X; Jiang S; Wang D; Ning F; Huang M; Jin J
Biochem Pharmacol; 2024 Jun; 224():116207. PubMed ID: 38621425
[TBL] [Abstract][Full Text] [Related]
31. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
[TBL] [Abstract][Full Text] [Related]
32. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
33. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
34. Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun SY
Mol Oncol; 2020 Apr; 14(4):882-895. PubMed ID: 32003107
[TBL] [Abstract][Full Text] [Related]
35. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.
Liang XM; Qin Q; Liu BN; Li XQ; Zeng LL; Wang J; Kong LP; Zhong DS; Sun LL
Acta Pharmacol Sin; 2021 Apr; 42(4):648-654. PubMed ID: 33414509
[TBL] [Abstract][Full Text] [Related]
36. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
[No Abstract] [Full Text] [Related]
37. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS
J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249
[TBL] [Abstract][Full Text] [Related]
39. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
Romaniello D; Mazzeo L; Mancini M; Marrocco I; Noronha A; Kreitman M; Srivastava S; Ghosh S; Lindzen M; Salame TM; Onn A; Bar J; Yarden Y
Clin Cancer Res; 2018 Nov; 24(22):5610-5621. PubMed ID: 29967248
[No Abstract] [Full Text] [Related]
40. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
